Arena and Eisai announced that the FDA has accepted the resubmitted New Drug Application (NDA) for lorcaserin for weight management, including weight loss and maintenance of weight loss, in patients who are obese (Body Mass Index [BMI] >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition.

Lorcaserin is an investigational new chemical entity that is believed to act as a selective serotonin 2C receptor agonist.

For more information, call (858) 453-7200 or visit